These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 9679785)

  • 1. The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease.
    Lawrence AD; Weeks RA; Brooks DJ; Andrews TC; Watkins LH; Harding AE; Robbins TW; Sahakian BJ
    Brain; 1998 Jul; 121 ( Pt 7)():1343-55. PubMed ID: 9679785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Huntington's disease progression. PET and clinical observations.
    Andrews TC; Weeks RA; Turjanski N; Gunn RN; Watkins LH; Sahakian B; Hodges JR; Rosser AE; Wood NW; Brooks DJ
    Brain; 1999 Dec; 122 ( Pt 12)():2353-63. PubMed ID: 10581228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.
    Antonini A; Leenders KL; Spiegel R; Meier D; Vontobel P; Weigell-Weber M; Sanchez-Pernaute R; de Yébenez JG; Boesiger P; Weindl A; Maguire RP
    Brain; 1996 Dec; 119 ( Pt 6)():2085-95. PubMed ID: 9010012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for specific cognitive deficits in preclinical Huntington's disease.
    Lawrence AD; Hodges JR; Rosser AE; Kershaw A; ffrench-Constant C; Rubinsztein DC; Robbins TW; Sahakian BJ
    Brain; 1998 Jul; 121 ( Pt 7)():1329-41. PubMed ID: 9679784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bradykinesia in early Huntington's disease.
    Sánchez-Pernaute R; Künig G; del Barrio Alba A; de Yébenes JG; Vontobel P; Leenders KL
    Neurology; 2000 Jan; 54(1):119-25. PubMed ID: 10636136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study.
    Pavese N; Andrews TC; Brooks DJ; Ho AK; Rosser AE; Barker RA; Robbins TW; Sahakian BJ; Dunnett SB; Piccini P
    Brain; 2003 May; 126(Pt 5):1127-35. PubMed ID: 12690052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of phosphodiesterase 10A, dopamine receptors D1 and D2 and dopamine transporter ligand binding in the striatum of the R6/2 and BACHD mouse models of Huntington's disease.
    Miller S; Hill Della Puppa G; Reidling J; Marcora E; Thompson LM; Treanor J
    J Huntingtons Dis; 2014; 3(4):333-41. PubMed ID: 25575954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease.
    van Oostrom JC; Dekker M; Willemsen AT; de Jong BM; Roos RA; Leenders KL
    Eur J Neurol; 2009 Feb; 16(2):226-31. PubMed ID: 19138335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease.
    Weeks RA; Piccini P; Harding AE; Brooks DJ
    Ann Neurol; 1996 Jul; 40(1):49-54. PubMed ID: 8687191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease.
    Ginovart N; Lundin A; Farde L; Halldin C; Bäckman L; Swahn CG; Pauli S; Sedvall G
    Brain; 1997 Mar; 120 ( Pt 3)():503-14. PubMed ID: 9126061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Striatal degeneration impairs language learning: evidence from Huntington's disease.
    De Diego-Balaguer R; Couette M; Dolbeau G; Dürr A; Youssov K; Bachoud-Lévi AC
    Brain; 2008 Nov; 131(Pt 11):2870-81. PubMed ID: 18842608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes.
    Bäckman L; Robins-Wahlin TB; Lundin A; Ginovart N; Farde L
    Brain; 1997 Dec; 120 ( Pt 12)():2207-17. PubMed ID: 9448576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study.
    Turjanski N; Weeks R; Dolan R; Harding AE; Brooks DJ
    Brain; 1995 Jun; 118 ( Pt 3)():689-96. PubMed ID: 7600086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [11C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length.
    Antonini A; Leenders KL; Eidelberg D
    Ann Neurol; 1998 Feb; 43(2):253-5. PubMed ID: 9485067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Executive and mnemonic functions in early Huntington's disease.
    Lawrence AD; Sahakian BJ; Hodges JR; Rosser AE; Lange KW; Robbins TW
    Brain; 1996 Oct; 119 ( Pt 5)():1633-45. PubMed ID: 8931586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thalamic metabolism and symptom onset in preclinical Huntington's disease.
    Feigin A; Tang C; Ma Y; Mattis P; Zgaljardic D; Guttman M; Paulsen JS; Dhawan V; Eidelberg D
    Brain; 2007 Nov; 130(Pt 11):2858-67. PubMed ID: 17893097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases.
    Seeman P; Bzowej NH; Guan HC; Bergeron C; Reynolds GP; Bird ED; Riederer P; Jellinger K; Tourtellotte WW
    Neuropsychopharmacology; 1987 Dec; 1(1):5-15. PubMed ID: 2908095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
    Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
    Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When does Huntington's disease begin?
    Campodonico JR; Aylward E; Codori AM; Young C; Krafft L; Magdalinski M; Ranen N; Slavney PR; Brandt J
    J Int Neuropsychol Soc; 1998 Sep; 4(5):467-73. PubMed ID: 9745236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia.
    Joyce JN; Lexow N; Bird E; Winokur A
    Synapse; 1988; 2(5):546-57. PubMed ID: 2973147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.